Table of Contents
Overview
New York, NY – June 27, 2025 – Global Image Guided Therapy System Market size is expected to be worth around US$ 9.4 Billion by 2034 from US$ 5.4 Billion in 2024, growing at a CAGR of 5.7% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 42.1% share with a revenue of US$ 2.2 Billion.
In 2024, the global Image-Guided Therapy (IGT) System market is experiencing significant momentum due to its critical role in enabling real-time visualization during complex medical procedures. These systems integrate advanced imaging technologies such as MRI, CT, ultrasound, and fluoroscopy with surgical platforms, helping clinicians perform minimally invasive interventions with enhanced precision and safety. The increasing burden of chronic diseases, including cancer and cardiovascular disorders, is driving adoption across hospitals, specialty clinics, and ambulatory surgical centers.
Image-guided therapy is especially valuable in oncology, neurosurgery, and orthopedic procedures, where it facilitates accurate targeting, reduces surgical complications, and improves patient recovery outcomes. Technological advancements such as robotic-assisted navigation, 3D imaging, and AI-driven diagnostic support are further elevating the system’s clinical efficacy.
North America currently leads the market, supported by well-established healthcare infrastructure and early technology adoption. However, the Asia Pacific region is anticipated to register the fastest CAGR, driven by growing healthcare investments, rising disease incidence, and adoption of precision medicine across emerging economies.
Key players are investing in R&D and strategic partnerships to enhance system integration and expand into underserved markets. As procedural accuracy and patient safety continue to shape healthcare delivery standards, the demand for integrated, real-time imaging solutions is expected to accelerate, positioning image-guided therapy systems as a cornerstone of modern surgical care.
Key Takeaways
- The global image-guided therapy system market was valued at US$ 5.4 billion in 2024 and is projected to reach approximately US$ 9.4 billion by 2034, expanding at a compound annual growth rate (CAGR) of 5.7% over the forecast period.
- By product type, the endoscope segment emerged as the dominant category in 2024, capturing 33.5% of the global revenue share, driven by its widespread use in minimally invasive procedures.
- In terms of application, cardiac surgery accounted for the largest share, contributing 30.4% to the total market revenue in 2024, owing to rising incidences of cardiovascular disorders and the demand for precision-based interventions.
- Based on end-users, the hospital segment led the market in 2024, holding a 36.8% revenue share, supported by increasing procedural volumes and investments in advanced surgical imaging technologies.
- North America maintained its dominant position in the global image-guided therapy system market, securing over 42.1% of the total revenue share in 2024, driven by a robust healthcare infrastructure and early adoption of cutting-edge imaging solutions.
Segmentation Analysis
- Product Analysis: In 2024, the endoscope segment led the image-guided therapy system market with a 33.5% share. This dominance stems from the growing preference for minimally invasive procedures that endoscopy supports through real-time internal visualization. Innovations like AI-assisted platforms such as Medtronic’s GI Genius and Olympus’s EVIS EXERA III enhance diagnostic and therapeutic outcomes. Rising cases of gastrointestinal disorders and cancers, coupled with high procedural volumes, continue to fuel the demand for endoscopic systems across multiple specialties.
- Connectivity Technology Analysis: Cardiac surgery accounted for the largest share in 2024, capturing 30.4% of the image-guided therapy system market. This growth is driven by the rising prevalence of cardiovascular diseases and the increasing adoption of minimally invasive techniques. Imaging technologies such as IVUS, fluoroscopy, and MRI aid in procedures like CABG and angioplasty. Advanced platforms like Philips’ Azurion and GE Healthcare’s Allia IGS 7 further support cardiac precision, especially in developed healthcare systems across North America and Europe.
- End-use Analysis: Hospitals dominated the global market in 2024 with a 36.8% share, driven by the high volume of complex procedures conducted in these settings. Their access to integrated imaging systems such as MRI, CT, and fluoroscopy enables precise navigation during surgeries. Hospitals also benefit from strong reimbursement policies and multidisciplinary capabilities. These advantages, along with a focus on minimally invasive procedures, ensure hospitals remain primary adopters of image-guided therapy systems worldwide.
Market Segments
By Product
- Endoscope
- Computed Tomography (CT) Scanners
- Ultrasound Systems
- Magnetic Resonance Imaging (MRI)
- X-ray Fluoroscopy
- Positron Emission Tomography (PET)
- Single Photon Emission Computed Tomography (SPECT)
By Connectivity Technology
- Cardiac Surgery
- Neurosurgery
- Orthopedic Surgery
- Urology
- Gastroenterology
- Oncology Surgery
- Others
By End-use
- Hospitals
- Ambulatory Surgical Centers
- Specialty Clinics
- Research & Academic Institutes
Regional Analysis
North America held the leading position in the global image-guided therapy (IGT) systems market in 2024, supported by robust healthcare infrastructure, advanced research and development (R&D) efforts, and the strong presence of prominent medical device manufacturers. The region benefits from substantial investments in emerging technologies such as artificial intelligence (AI), robotics, and augmented reality, which have significantly enhanced the precision, efficiency, and outcomes of image-guided procedures.
These technological advancements facilitate minimally invasive surgeries across specialties such as cardiology, oncology, and neurology, contributing to reduced recovery times and improved patient outcomes. The United States, in particular, is home to leading hospitals and medical research institutions that actively adopt and integrate next-generation imaging systems.
In June 2023, the U.S. FDA approved Daiichi Sankyo’s INJECTAFER for iron deficiency treatment in adult heart failure patients, underscoring the country’s commitment to advancing medical therapies. Furthermore, the presence of major industry players such as Medtronic, Philips, and Siemens Healthineers drives continuous innovation and competitive excellence in the market.
These factors collectively reinforce North America’s leadership in the IGT systems market, as hospitals across the region prioritize precision guided interventions to enhance clinical care and meet the growing demand for high-performance therapeutic solutions.
Emerging Trends
- Adoption of Artificial Intelligence and Machine Learning: The integration of AI/ML algorithms into image-guided therapy systems is being actively encouraged to improve procedural accuracy and personalize treatment plans. The FDA’s AI/ML-Enabled Medical Device List—current as of March 25, 2025 demonstrates a growing number of AI/ML-enabled devices being cleared for marketing, reflecting this trend toward intelligent guidance and automation in therapy delivery.
- Integration of Augmented Reality and Virtual Reality: Immersive AR/VR technologies are increasingly incorporated into planning and navigation tools for image-guided therapy. As of September 6, 2024, the FDA had authorized 69 medical devices that leverage AR/VR to overlay critical anatomical information in real time, helping clinicians enhance precision during minimally invasive procedures.
- Standardization of Real-Time X-Ray Guidance in Radiotherapy: Consensus standards for offline, online and real-time X-IGRT (image-guided radiotherapy) equipment have been published to ensure uniform safety and performance criteria. This move toward standardized real-time imaging workflows is intended to reduce reliance on intermittent imaging and optimize radiation dosing during treatment.
Use Cases
- Intraoperative Fluorescence-Guided Cancer Surgery: The FDA approved Lumisight (pegulicianine) in 2024 for use during breast cancer lumpectomy to highlight residual cancerous tissue within the surgical cavity. The fluorescent imaging drug is administered intravenously prior to surgery, aiding surgeons in detecting microscopic tumor remnants and reducing re-excision rates.
- Fluoroscopy-Guided Catheter and Stent Placement: Fluoroscopy delivers real-time X-ray video to guide catheter positioning, stent deployment and orthopedic hardware placement. According to the CDC, fluoroscopy uses continuous imaging to capture internal motion, and this modality underpins millions of vascular and musculoskeletal interventions annually.
- Emergency Department CT/MRI-Guided Diagnostics: Diagnostic CT and MRI scans have become integral to emergency care, with the percentage of ED visits involving CT or MRI imaging rising from 6% in 2001 to 17% by 2010. This increase underscores the reliance on cross-sectional imaging to rapidly diagnose trauma, stroke and acute cardiovascular events.
Conclusion
The global image-guided therapy (IGT) systems market is poised for sustained growth, projected to reach US$ 9.4 billion by 2034. This expansion is driven by rising demand for minimally invasive procedures, advancements in imaging technologies, and increasing prevalence of chronic conditions. North America leads due to robust infrastructure and early adoption, while Asia Pacific is expected to grow rapidly.
Integration of AI, AR/VR, and standardized real-time imaging continues to enhance precision and efficiency. Supported by strong R&D, strategic partnerships, and regulatory advancements, IGT systems are becoming essential tools in modern surgical care, improving outcomes and setting new standards in patient safety.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
